Eventide Asset Management’s Cullinan Oncology CGEM Stock Holding History

Eventide Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,440,145	Closed	-$15.1M	–	139
2022 Q1	$15.1M	Hold	1,440,145	–	–	0.24%	98
2021 Q4	$21.7M	Hold	1,440,145	–	–	0.28%	93
2021 Q3	$31.7M	Hold	1,440,145	–	–	0.42%	75
2021 Q2	$36.2M	Buy	1,440,145 +227,590	+19%	+$7M	0.49%	63
2021 Q1	$49M	Buy	+1,212,555	New	+$49.2M	0.73%	50

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Eventide Asset Management's CGEM Position: Q2 2022 in Review

Eventide Asset Management sold out of Cullinan Oncology (CGEM) in Q2 2022, closing a stake of 1,440,145 shares — an estimated $15.1M sold.

Eventide Asset Management first reported a position in CGEM in Q1 2021 and held it in 5 quarters. The position peaked at $49M in Q1 2021. 89 funds tracked by Wall St. Rank hold CGEM as of Q2 2022.

Eventide Asset Management reported no remaining Cullinan Oncology position as of Q2 2022 after selling out during the quarter.
Eventide Asset Management sold 1,440,145 Cullinan Oncology shares in Q2 2022, an estimated $15.1M.
Eventide Asset Management first reported a position in Cullinan Oncology in Q1 2021 and held it in 5 quarters.
Eventide Asset Management's Cullinan Oncology position peaked at $49M in Q1 2021.
89 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2022.

Based on Eventide Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.